Vertex INCIVEK sales likely to decline further, says Piper Jaffray After the FDA forced Vertex to place a warning regarding fatal and non-fatal serious skin reactions on the boxes containing its INCIVEK HCV treatment, Piper Jaffray expects sales of the drug to decline further. The firm maintains a Neutral rating on the stock.
News For VRTX From The Last 14 Days
Check below for free stories on VRTX the last two weeks.
Vertex shares should be owned ahead of data, says JMP Securities JMP Securities expects Phase 3 data for Kalydeco in combination with corrector lumacaftor, expected to be announced mid-year, to be positive. It recommends that ivnestors own the stock ahead of the data. The firm notes that Vertex received a label expansion for Kalydeco fro mthe FDA, and it reiterates a $115 price target and Outperform rating on the stock.